{"hands_on_practices": [{"introduction": "A key pathological finding in reflux nephropathy is that scarring predominantly affects the renal poles. This practice delves into the biophysical reasons for this pattern, using a model based on Poiseuille's law of fluid dynamics. By exploring the relationship between the radius of collecting duct orifices and the volume of retrograde urine flow, you will quantitatively understand why the unique anatomy of the renal poles makes them more vulnerable to injury [@problem_id:4345576].", "problem": "A central question in the pathogenesis of chronic pyelonephritis with reflux nephropathy is why intrarenal reflux preferentially occurs at polar compound papillae compared with midzone simple papillae. Consider a mechanistic model grounded in well-established fluid dynamics and renal microanatomy: during a vesicoureteral reflux (VUR) episode, urine under a common transient pressure gradient is driven retrograde toward collecting duct orifices. Approximating each orifice as a short cylindrical conduit, and assuming steady laminar entry flow with the same pressure drop and fluid properties across sites, the volumetric inflow rate into a duct is governed by viscous (Poiseuille) flow in a cylinder. Let the viscosity and conduit length be comparable between polar and midzone papillae so that differences in inflow are dominated by orifice radius. If the probability of parenchymal inoculation during a reflux event is proportional to the volumetric inflow into the duct orifices, then the relative risk between sites scales with the ratio of their volumetric inflows.\n\nGiven a representative polar papilla orifice radius of $r_{\\text{polar}}=60\\,\\mu\\text{m}$ and a midzone papilla orifice radius of $r_{\\text{mid}}=30\\,\\mu\\text{m}$, compute the unitless ratio $R$ of intrarenal reflux risk at polar papillae to that at midzone papillae under the stated assumptions. Provide the exact value of $R$ with no rounding.", "solution": "The problem will first be validated for scientific and logical integrity.\n\n### Step 1: Extract Givens\n- **Context**: Pathogenesis of chronic pyelonephritis with reflux nephropathy.\n- **Observation**: Intrarenal reflux preferentially occurs at polar compound papillae compared with midzone simple papillae.\n- **Model**: Vesicoureteral reflux (VUR) drives urine retrograde into collecting duct orifices.\n- **Approximation**: Each orifice is a short cylindrical conduit.\n- **Flow Assumptions**:\n    - Steady laminar entry flow.\n    - The pressure drop, $\\Delta P$, is the same across all sites.\n    - The fluid (urine) viscosity, $\\mu$, is the same.\n    - The conduit length, $L$, is comparable and treated as the same.\n    - Volumetric inflow rate, $Q$, is governed by viscous (Poiseuille) flow.\n- **Risk Assumption**: The probability of parenchymal inoculation is proportional to the volumetric inflow rate, $Q$.\n- **Definition of Relative Risk**: The relative risk, $R$, between sites scales with the ratio of their volumetric inflows, $R = \\frac{Q_{\\text{polar}}}{Q_{\\text{mid}}}$.\n- **Data**:\n    - Polar papilla orifice radius: $r_{\\text{polar}} = 60\\,\\mu\\text{m}$.\n    - Midzone papilla orifice radius: $r_{\\text{mid}} = 30\\,\\mu\\text{m}$.\n- **Objective**: Compute the unitless ratio $R$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity.\n- **Scientifically Grounded**: The problem is well-grounded in established principles of renal pathophysiology and fluid dynamics. The observation regarding preferential reflux at polar papillae is a known phenomenon attributed to the anatomical differences in collecting duct orifices (ducts of Bellini), where polar papillae are often compound and have wider, gaping orifices. Modeling this using Poiseuille's law for pipe flow is a standard and appropriate biophysical simplification.\n- **Well-Posed**: The problem is well-posed. It provides a clear physical model, defines all necessary relationships and assumptions (proportionality of risk to flow, constancy of $\\Delta P$, $\\mu$, and $L$), and supplies all required numerical data to arrive at a unique solution.\n- **Objective**: The problem is stated in objective, quantitative terms, free from subjective or speculative language.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is a sound application of fluid dynamics principles to a well-defined problem in pathophysiology. A solution will now be derived.\n\nThe volumetric flow rate, $Q$, of a viscous fluid through a cylindrical pipe under conditions of steady, laminar flow is described by the Hagen-Poiseuille equation:\n$$Q = \\frac{\\pi (\\Delta P) r^{4}}{8 \\mu L}$$\nwhere $r$ is the radius of the cylinder, $\\Delta P$ is the pressure drop over the length $L$ of the cylinder, and $\\mu$ is the dynamic viscosity of the fluid.\n\nThe problem states that the risk of parenchymal inoculation is proportional to the volumetric inflow rate, $Q$. Therefore, the relative risk, $R$, of reflux at a polar papilla compared to a midzone papilla is the ratio of their respective volumetric flow rates:\n$$R = \\frac{Q_{\\text{polar}}}{Q_{\\text{mid}}}$$\nWe can write the flow rates for the polar and midzone papillae using the Hagen-Poiseuille equation:\n$$Q_{\\text{polar}} = \\frac{\\pi (\\Delta P) r_{\\text{polar}}^{4}}{8 \\mu L}$$\n$$Q_{\\text{mid}} = \\frac{\\pi (\\Delta P) r_{\\text{mid}}^{4}}{8 \\mu L}$$\nThe problem posits that the pressure drop $\\Delta P$, viscosity $\\mu$, and length $L$ are the same for both types of papillary orifices. Thus, when we compute the ratio $R$, these common terms cancel out:\n$$R = \\frac{\\frac{\\pi (\\Delta P) r_{\\text{polar}}^{4}}{8 \\mu L}}{\\frac{\\pi (\\Delta P) r_{\\text{mid}}^{4}}{8 \\mu L}} = \\frac{r_{\\text{polar}}^{4}}{r_{\\text{mid}}^{4}}$$\nThis simplifies to:\n$$R = \\left(\\frac{r_{\\text{polar}}}{r_{\\text{mid}}}\\right)^{4}$$\nThe problem provides the following values for the radii: $r_{\\text{polar}} = 60\\,\\mu\\text{m}$ and $r_{\\text{mid}} = 30\\,\\mu\\text{m}$. Substituting these values into the expression for $R$:\n$$R = \\left(\\frac{60\\,\\mu\\text{m}}{30\\,\\mu\\text{m}}\\right)^{4}$$\nThe units of micrometers ($\\mu\\text{m}$) cancel, yielding a dimensionless ratio as required:\n$$R = \\left(\\frac{60}{30}\\right)^{4} = 2^{4}$$\nCalculating the final value:\n$$R = 16$$\nThis result demonstrates that under the stated model, the risk of significant intrarenal reflux is $16$ times greater at the polar papillae than at the midzone papillae, a finding that is highly consistent with clinical and pathological observations. The strong dependence of flow on the fourth power of the radius is the critical factor explaining this marked difference.", "answer": "$$\\boxed{16}$$", "id": "4345576"}, {"introduction": "In clinical practice, distinguishing tubulointerstitial disease from glomerular disease is a crucial diagnostic step. This exercise challenges you to act like a clinician, interpreting common laboratory tests—the urine protein-creatinine ratio ($UPCR$) and the fractional excretion of sodium ($FENa$)—in the context of a patient's history. By analyzing these data, you will learn to recognize the classic physiological signature of chronic pyelonephritis [@problem_id:4345626].", "problem": "A patient with a history of recurrent urinary tract infections since childhood and documented vesicoureteral reflux presents for evaluation of chronic kidney changes. Ultrasonography shows cortical thinning with irregular, coarse corticomedullary scarring and calyceal clubbing. A spot urine yields a urine protein-to-creatinine ratio of $0.4$ (interpreted in grams protein per gram creatinine), and measurements of urine and plasma electrolytes and creatinine give a fractional excretion of sodium of $\\mathrm{FENa} = 1.5\\%$. Consider the foundational renal physiology:\n\n- Glomerular filtration delivers solute and water to the tubule; tubular segments reabsorb a large fraction of filtered sodium and normally restrict protein loss by relying on an intact glomerular filtration barrier and efficient proximal tubular endocytic recovery of low-molecular-weight proteins.\n- The fractional excretion of sodium is defined as $$\\mathrm{FENa} = \\frac{C_{\\mathrm{Na}}}{C_{\\mathrm{Cr}}} \\times 100\\% = \\frac{\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{U}} \\times \\mathrm{Cr}_{\\mathrm{S}}}{\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{S}} \\times \\mathrm{Cr}_{\\mathrm{U}}} \\times 100\\%,$$ where $C_{\\mathrm{Na}}$ and $C_{\\mathrm{Cr}}$ are the clearances of sodium and creatinine, $\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{U}}$ and $\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{S}}$ are urine and serum sodium concentrations, and $\\mathrm{Cr}_{\\mathrm{U}}$ and $\\mathrm{Cr}_{\\mathrm{S}}$ are urine and serum creatinine concentrations. An elevated $\\mathrm{FENa}$ indicates impaired tubular sodium reabsorption.\n- The urine protein-to-creatinine ratio ($\\mathrm{UPCR}$) approximates daily protein excretion in grams per day; values $< 0.2$ generally indicate minimal proteinuria, values around $0.3$ to $1.0$ reflect non-nephrotic proteinuria, and values $\\geq 3.5$ reflect nephrotic-range proteinuria.\n\nUsing these data, which option best classifies the predominant site of injury and provides the most coherent mechanistic explanation in the setting of chronic pyelonephritis and reflux nephropathy?\n\nA. Tubulointerstitial predominant injury consistent with reflux nephropathy; the elevated $\\mathrm{FENa}$ ($> 1\\%$) indicates impaired tubular sodium reabsorption, and $\\mathrm{UPCR} = 0.4$ indicates non-nephrotic proteinuria typical of tubular protein loss and interstitial scarring rather than primary glomerular barrier failure.\n\nB. Primary glomerular (glomerulonephritis) predominant injury; $\\mathrm{UPCR} = 0.4$ signifies nephrotic-range albuminuria from a leaky glomerular filtration barrier, and $\\mathrm{FENa}$ should be $< 1\\%$ if tubules are intact.\n\nC. Prerenal hypoperfusion pattern; a low $\\mathrm{FENa}$ ($< 1\\%$) and minimal proteinuria would be expected, consistent with intact tubular reabsorption of sodium and preserved glomerular barrier function.\n\nD. Acute interstitial nephritis; the elevated $\\mathrm{FENa}$ and modest proteinuria reflect tubular dysfunction from a drug-induced hypersensitivity reaction, the most likely explanation of the chronic scarring and calyceal changes described.", "solution": "## Problem Validation ##\n\n### Step 1: Extract Givens ###\nThe problem statement provides the following information:\n1.  **Patient History:** Recurrent urinary tract infections since childhood; documented vesicoureteral reflux.\n2.  **Clinical Presentation:** Chronic kidney changes.\n3.  **Imaging Findings (Ultrasonography):** Cortical thinning with irregular, coarse corticomedullary scarring and calyceal clubbing.\n4.  **Laboratory Data:**\n    -   Urine protein-to-creatinine ratio ($\\mathrm{UPCR}$) = $0.4$ (grams protein per gram creatinine).\n    -   Fractional excretion of sodium ($\\mathrm{FENa}$) = $1.5\\%$.\n5.  **Physiological Principles and Definitions:**\n    -   Glomerular filtration and tubular reabsorption of sodium and protein are described.\n    -   The formula for fractional excretion of sodium is given: $$\\mathrm{FENa} = \\frac{C_{\\mathrm{Na}}}{C_{\\mathrm{Cr}}} \\times 100\\% = \\frac{\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{U}} \\times \\mathrm{Cr}_{\\mathrm{S}}}{\\left(\\mathrm{Na}^{+}\\right)_{\\mathrm{S}} \\times \\mathrm{Cr}_{\\mathrm{U}}} \\times 100\\%$$\n    -   Interpretation of $\\mathrm{FENa}$: An elevated $\\mathrm{FENa}$ indicates impaired tubular sodium reabsorption.\n    -   Interpretation of $\\mathrm{UPCR}$:\n        -   $\\mathrm{UPCR} < 0.2$ indicates minimal proteinuria.\n        -   $\\mathrm{UPCR}$ from $0.3$ to $1.0$ reflects non-nephrotic proteinuria.\n        -   $\\mathrm{UPCR} \\geq 3.5$ reflects nephrotic-range proteinuria.\n6.  **Question:** Classify the predominant site of injury and provide the most coherent mechanistic explanation in the context of chronic pyelonephritis and reflux nephropathy.\n\n### Step 2: Validate Using Extracted Givens ###\nThe problem is assessed against the validation criteria:\n-   **Scientifically Grounded:** The problem describes a classic clinical presentation of reflux nephropathy (a form of chronic pyelonephritis). The association between vesicoureteral reflux (VUR), recurrent urinary tract infections (UTIs), and the specific renal parenchymal changes (cortical scarring, calyceal clubbing) is a cornerstone of nephrology and urology. The laboratory values ($\\mathrm{FENa}$ and $\\mathrm{UPCR}$) and their provided interpretations are standard physiological and clinical measures used to differentiate types of kidney injury. All information is factually correct and based on established medical science.\n-   **Well-Posed:** The problem is well-posed. It provides a detailed clinical scenario with specific history, imaging, and laboratory findings. The question asks for an integration of these data to arrive at a specific pathophysiological diagnosis, which is a standard form of clinical reasoning. The information is sufficient and internally consistent, allowing for a unique and logical conclusion.\n-   **Objective:** The problem statement is objective, relying on clinical observations (VUR, UTIs), imaging descriptions (scarring, clubbing), and quantitative laboratory data ($\\mathrm{FENa} = 1.5\\%$, $\\mathrm{UPCR} = 0.4$). There are no subjective or opinion-based statements in the problem setup.\n-   **No other flaws detected:** The problem is not incomplete, contradictory, unrealistic, ill-posed, or trivial. It requires the application of fundamental principles of renal pathophysiology to interpret a coherent set of clinical data.\n\n### Step 3: Verdict and Action ###\nThe problem statement is **valid**. The solution process will proceed.\n\n## Solution Derivation ##\n\nThe goal is to synthesize the provided clinical history, imaging findings, and laboratory data into a coherent pathophysiological explanation.\n\n1.  **Analysis of History and Imaging:** The patient's history of recurrent UTIs since childhood combined with documented vesicoureteral reflux is the classic etiology for **chronic pyelonephritis**, also known as **reflux nephropathy**. Vesicoureteral reflux allows infected urine to flow backward from the bladder into the kidneys, leading to recurrent infections of the renal parenchyma (pyelonephritis). Over time, these recurrent inflammatory episodes cause healing with fibrosis, resulting in the characteristic imaging findings: coarse, irregular scarring of the renal cortex (often overlying a dilated, blunted calyx), cortical thinning, and **calyceal clubbing** (blunting and deformation of the calyces). These features strongly point to a primary disease process affecting the renal tubules and interstitium, not the glomeruli.\n\n2.  **Analysis of Laboratory Data:**\n    -   **$\\mathrm{FENa} = 1.5\\%$**: The problem defines an elevated $\\mathrm{FENa}$ as indicative of impaired tubular sodium reabsorption. A typical threshold used to distinguish prerenal states (where tubules function avidly to retain sodium, $\\mathrm{FENa} < 1\\%$) from intrinsic renal injury with tubular damage (where sodium reabsorption is impaired, $\\mathrm{FENa} > 1\\%$) is $1\\%$. The patient's value of $1.5\\%$ is elevated, providing direct evidence of **tubular dysfunction**. This is a hallmark of tubulointerstitial diseases like chronic pyelonephritis.\n    -   **$\\mathrm{UPCR} = 0.4$**: According to the provided scale, this value constitutes **non-nephrotic proteinuria**. Proteinuria in the nephrotic range ($\\mathrm{UPCR} \\geq 3.5$) is typically caused by severe damage to the glomerular filtration barrier (i.e., a primary glomerulopathy). In contrast, milder proteinuria is characteristic of tubulointerstitial diseases. This proteinuria has two main components in such diseases: 1) **Tubular proteinuria**, which results from the failure of damaged proximal tubules to reabsorb normally filtered low-molecular-weight proteins, and 2) Mild glomerular proteinuria, which can occur due to secondary glomerular sclerosis (focal segmental glomerulosclerosis, FSGS) that often develops in kidneys scarred from chronic pyelonephritis. The observed value of $0.4$ is perfectly consistent with this pattern and argues against a primary glomerular disease with massive protein leakage.\n\n3.  **Synthesis:** The patient's presentation is a textbook case of reflux nephropathy, a form of chronic tubulointerstitial nephritis. The history and imaging establish the diagnosis. The laboratory findings provide the physiological confirmation: the elevated $\\mathrm{FENa}$ points to impaired tubular sodium handling, and the non-nephrotic $\\mathrm{UPCR}$ points to protein loss characteristic of tubular dysfunction and/or secondary glomerular scarring, rather than a primary, severe glomerulopathy. The predominant site of injury is unequivocally the **tubulointerstitium**.\n\n## Option-by-Option Analysis ##\n\n**A. Tubulointerstitial predominant injury consistent with reflux nephropathy; the elevated $\\mathrm{FENa}$ ($> 1\\%$) indicates impaired tubular sodium reabsorption, and $\\mathrm{UPCR} = 0.4$ indicates non-nephrotic proteinuria typical of tubular protein loss and interstitial scarring rather than primary glomerular barrier failure.**\nThis option correctly identifies the site of injury as tubulointerstitial and the disease as reflux nephropathy, consistent with the history and imaging. It correctly interprets the elevated $\\mathrm{FENa}$ ($1.5\\% > 1\\%$) as a sign of tubular dysfunction. It also correctly classifies the proteinuria ($\\mathrm{UPCR} = 0.4$) as non-nephrotic and attributes it to mechanisms characteristic of tubulointerstitial disease. This explanation is fully coherent with all provided data.\n**Verdict: Correct**\n\n**B. Primary glomerular (glomerulonephritis) predominant injury; $\\mathrm{UPCR} = 0.4$ signifies nephrotic-range albuminuria from a leaky glomerular filtration barrier, and $\\mathrm{FENa}$ should be $< 1\\%$ if tubules are intact.**\nThis option is incorrect on multiple grounds. First, the history and imaging are not characteristic of a primary glomerulonephritis but of reflux nephropathy. Second, it falsely claims that $\\mathrm{UPCR} = 0.4$ signifies \"nephrotic-range\" proteinuria, which directly contradicts the provided definition ($\\geq 3.5$) and established medical knowledge. Third, while the statement that $\\mathrm{FENa}$ should be low if tubules are intact is physiologically correct in some contexts, the patient's measured $\\mathrm{FENa}$ is $1.5\\%$, indicating that the tubules are, in fact, *not* intact.\n**Verdict: Incorrect**\n\n**C. Prerenal hypoperfusion pattern; a low $\\mathrm{FENa}$ ($< 1\\%$) and minimal proteinuria would be expected, consistent with intact tubular reabsorption of sodium and preserved glomerular barrier function.**\nThis option describes a prerenal state (e.g., due to dehydration or heart failure), which is an acute condition characterized by renal hypoperfusion. The patient has a chronic disease process with structural scarring. Furthermore, the patient's data ($\\mathrm{FENa} = 1.5\\%$, $\\mathrm{UPCR} = 0.4$) directly contradict the expected findings of a prerenal pattern (low $\\mathrm{FENa} < 1\\%$ and minimal proteinuria).\n**Verdict: Incorrect**\n\n**D. Acute interstitial nephritis; the elevated $\\mathrm{FENa}$ and modest proteinuria reflect tubular dysfunction from a drug-induced hypersensitivity reaction, the most likely explanation of the chronic scarring and calyceal changes described.**\nThis option incorrectly diagnoses \"acute\" interstitial nephritis (AIN). The patient's findings (scarring, childhood onset) are explicitly chronic. While AIN can cause an elevated $\\mathrm{FENa}$ and modest proteinuria, it is an acute condition, typically due to drugs or infections, and does not explain the long-standing history dating to childhood or the classic imaging of reflux nephropathy. Attributing the chronic changes to drug-induced AIN is a much less likely and less direct explanation than chronic pyelonephritis secondary to VUR, which is explicitly mentioned in the history.\n**Verdict: Incorrect**", "answer": "$$\\boxed{A}$$", "id": "4345626"}, {"introduction": "Managing chronic kidney disease involves not just treating symptoms but also slowing the loss of function over time. This practice demonstrates how a simple mathematical model can be used to forecast the progression of reflux nephropathy and quantify the impact of therapy. By calculating the decline in estimated Glomerular Filtration Rate ($eGFR$), you can appreciate the profound, long-term benefits of interventions like ACE inhibitors in preserving kidney function [@problem_id:4345575].", "problem": "A patient with chronic pyelonephritis due to vesicoureteral reflux (reflux nephropathy) experiences progressive nephron loss and scarring, which reduces the glomerular filtration capacity. The estimated glomerular filtration rate (eGFR) can be modeled as the sum of single-nephron filtration, and under sustained injury the decline in eGFR over time can be approximated as linear. Consider the following assumptions grounded in well-tested clinical observations: (i) under constant injurious burden, eGFR declines at a constant rate, and (ii) angiotensin-converting enzyme (ACE) inhibitor therapy reduces intraglomerular pressure and proteinuric injury, thereby reducing the rate of decline.\n\nLet $G(t)$ denote the eGFR indexed to $1.73\\,\\text{m}^2$ body surface area at time $t$ (in years), with a baseline value $G(0)=G_{0}$ and a constant decline rate $r>0$ in the absence of therapy. The fundamental base is that, to first approximation in the chronic phase, the time evolution satisfies the constant-rate ordinary differential equation\n$$\\frac{dG}{dt}=-r,$$\nand that under ACE inhibitor therapy the rate is halved to $r/2$.\n\nA patient presents with baseline eGFR $G_{0} = 85\\,\\text{mL/min/1.73}\\,\\text{m}^2$ and an observed annual decline $r = 3\\,\\text{mL/min/1.73}\\,\\text{m}^2$ in the absence of therapy. Determine:\n1. The time $t_{\\text{noACE}}$ required for the eGFR to reach $G_{\\ast}=60\\,\\text{mL/min/1.73}\\,\\text{m}^2$ without ACE inhibitor therapy.\n2. The time $t_{\\text{ACE}}$ required to reach the same $G_{\\ast}$ if ACE inhibitor therapy halves the decline rate from $r$ to $r/2$.\n3. The delay $\\Delta t = t_{\\text{ACE}} - t_{\\text{noACE}}$ attributable to ACE inhibitor therapy.\n\nExpress all times in years. Provide exact values; do not round. Your final answer should list the three quantities $\\left(t_{\\text{noACE}},\\,t_{\\text{ACE}},\\,\\Delta t\\right)$ as a single row matrix.", "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in the principles of nephrology concerning chronic kidney disease progression and the therapeutic effect of ACE inhibitors. The problem is well-posed, providing a clear initial value problem with all necessary data for a unique solution. The model, while a simplification, is a standard and useful first-order approximation in clinical contexts.\n\nThe problem describes the time evolution of the estimated Glomerular Filtration Rate, $G(t)$, by the ordinary differential equation\n$$\n\\frac{dG}{dt} = -k\n$$\nwhere $k$ is the constant rate of decline. The initial condition is given as $G(0) = G_0$. This is a first-order linear ordinary differential equation that can be solved by direct integration with respect to time $t$:\n$$\n\\int_{G_0}^{G(t)} dG' = \\int_{0}^{t} -k \\, dt'\n$$\n$$\nG(t) - G_0 = -kt\n$$\nThis gives the explicit function for $G(t)$ as:\n$$\nG(t) = G_0 - kt\n$$\nThe problem provides the following values:\nBaseline eGFR: $G_0 = 85\\,\\text{mL/min/1.73}\\,\\text{m}^2$.\nTarget eGFR: $G_{\\ast} = 60\\,\\text{mL/min/1.73}\\,\\text{m}^2$.\nDecline rate without therapy: $r = 3\\,\\text{mL/min/1.73}\\,\\text{m}^2$ per year.\n\nWe are asked to determine three quantities: $t_{\\text{noACE}}$, $t_{\\text{ACE}}$, and $\\Delta t$.\n\n1.  Time to reach $G_{\\ast}$ without ACE inhibitor therapy ($t_{\\text{noACE}}$).\nIn this scenario, the rate of decline is $k=r$. The equation for the eGFR is:\n$$\nG(t) = G_0 - rt\n$$\nWe need to find the time $t = t_{\\text{noACE}}$ such that $G(t_{\\text{noACE}}) = G_{\\ast}$.\n$$\nG_{\\ast} = G_0 - r t_{\\text{noACE}}\n$$\nSolving for $t_{\\text{noACE}}$ yields:\n$$\nr t_{\\text{noACE}} = G_0 - G_{\\ast}\n$$\n$$\nt_{\\text{noACE}} = \\frac{G_0 - G_{\\ast}}{r}\n$$\nSubstituting the numerical values:\n$$\nt_{\\text{noACE}} = \\frac{85 - 60}{3} = \\frac{25}{3}\n$$\nSo, the time required without therapy is $\\frac{25}{3}$ years.\n\n2.  Time to reach $G_{\\ast}$ with ACE inhibitor therapy ($t_{\\text{ACE}}$).\nIn this scenario, the therapy halves the rate of decline, so the new rate is $k = r/2$. The equation for the eGFR is:\n$$\nG(t) = G_0 - \\frac{r}{2}t\n$$\nWe need to find the time $t = t_{\\text{ACE}}$ such that $G(t_{\\text{ACE}}) = G_{\\ast}$.\n$$\nG_{\\ast} = G_0 - \\frac{r}{2} t_{\\text{ACE}}\n$$\nSolving for $t_{\\text{ACE}}$ yields:\n$$\n\\frac{r}{2} t_{\\text{ACE}} = G_0 - G_{\\ast}\n$$\n$$\nt_{\\text{ACE}} = \\frac{2(G_0 - G_{\\ast})}{r}\n$$\nSubstituting the numerical values:\n$$\nt_{\\text{ACE}} = \\frac{2(85 - 60)}{3} = \\frac{2(25)}{3} = \\frac{50}{3}\n$$\nSo, the time required with therapy is $\\frac{50}{3}$ years.\n\n3.  The delay $\\Delta t$ attributable to ACE inhibitor therapy.\nThe delay is defined as the difference between the time to reach the target with therapy and the time without therapy.\n$$\n\\Delta t = t_{\\text{ACE}} - t_{\\text{noACE}}\n$$\nUsing the symbolic expressions derived above:\n$$\n\\Delta t = \\frac{2(G_0 - G_{\\ast})}{r} - \\frac{G_0 - G_{\\ast}}{r} = \\frac{G_0 - G_{\\ast}}{r}\n$$\nThis demonstrates that the delay imparted by halving the rate of decline is equal to the original time to progression.\nSubstituting the calculated values:\n$$\n\\Delta t = \\frac{50}{3} - \\frac{25}{3} = \\frac{25}{3}\n$$\nSo, the delay is $\\frac{25}{3}$ years.\n\nThe three requested quantities are $(t_{\\text{noACE}}, t_{\\text{ACE}}, \\Delta t) = \\left(\\frac{25}{3}, \\frac{50}{3}, \\frac{25}{3}\\right)$ years.", "answer": "$$\n\\boxed{\\begin{pmatrix} \\frac{25}{3} & \\frac{50}{3} & \\frac{25}{3} \\end{pmatrix}}\n$$", "id": "4345575"}]}